Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics.
Alnylam Pharmaceuticals has partnered with Dicerna Pharmaceuticals to develop and commercialise ribonucleic acid interference (RNAi) therapies to treat alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.